CA2218808A1 - Improved retroviral vectors, especially suitable for gene therapy - Google Patents

Improved retroviral vectors, especially suitable for gene therapy Download PDF

Info

Publication number
CA2218808A1
CA2218808A1 CA 2218808 CA2218808A CA2218808A1 CA 2218808 A1 CA2218808 A1 CA 2218808A1 CA 2218808 CA2218808 CA 2218808 CA 2218808 A CA2218808 A CA 2218808A CA 2218808 A1 CA2218808 A1 CA 2218808A1
Authority
CA
Canada
Prior art keywords
gene
cells
vector
vector according
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2218808
Other languages
English (en)
French (fr)
Inventor
Ronald Vogels
Johannes Jozephes Bernandus Boesen
Helmuth Hendrikus Gerardus Van Es
Victor Willem Van Beusechem
Domenico Valerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgene BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2218808A1 publication Critical patent/CA2218808A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA 2218808 1995-05-10 1996-05-07 Improved retroviral vectors, especially suitable for gene therapy Abandoned CA2218808A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95201211 1995-05-10
EP95201211.0 1995-05-10

Publications (1)

Publication Number Publication Date
CA2218808A1 true CA2218808A1 (en) 1996-11-14

Family

ID=8220283

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2218808 Abandoned CA2218808A1 (en) 1995-05-10 1996-05-07 Improved retroviral vectors, especially suitable for gene therapy

Country Status (5)

Country Link
EP (1) EP0835320A1 (de)
JP (1) JPH11511651A (de)
AU (1) AU5703796A (de)
CA (1) CA2218808A1 (de)
WO (1) WO1996035798A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500740A (en) 1997-05-13 2001-02-23 Univ North Carolina Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
AU6267000A (en) * 1999-06-30 2001-01-22 Evotec Oai Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
JP2007535329A (ja) * 2004-04-29 2007-12-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 細胞接着性を増強する方法および組成物
WO2008108344A1 (ja) * 2007-03-02 2008-09-12 Cellgentech, Inc. Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959313A (en) * 1987-06-22 1990-09-25 The Jackson Laboratory Cellular enhancer for expressing genes in undifferentiated stem cells
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
WO1994029437A1 (en) * 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5631162A (en) * 1993-06-11 1997-05-20 Massachusetts Institute Of Technology Retroviral vectors for transducing β-globin gene and β-locus control region derivatives
US5707865A (en) * 1994-12-21 1998-01-13 Kohn; Donald B. Retroviral vectors for expression in embryonic cells

Also Published As

Publication number Publication date
JPH11511651A (ja) 1999-10-12
WO1996035798A1 (en) 1996-11-14
AU5703796A (en) 1996-11-29
EP0835320A1 (de) 1998-04-15

Similar Documents

Publication Publication Date Title
Vile et al. Retroviruses as vectors
US6312948B1 (en) Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells
Miller et al. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene
US5952225A (en) Retroviral vectors produced by producer cell lines resistant to lysis by human serum
EP1059357A1 (de) Replizierende oder 'semi-replizierende' retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
US20110294873A1 (en) Gene Transfer Vectors Comprising At Least One Isolated DNA Molecule Having Insulator Or Boundary Properties And Methods To Identify The Same
CA2218808A1 (en) Improved retroviral vectors, especially suitable for gene therapy
US7056730B2 (en) Expression of heterologous genes from an IRES translational cassette in retroviral vectors
US6190907B1 (en) Retroviral vectors for gene therapy
Haviernik et al. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors
AU721326B2 (en) 10A1 retroviral packaging cells and uses thereof
METZ et al. Bicistronic and two-gene retroviral vectors for usingMDR1 as a selectable marker and a therapeutic gene
Havenga et al. Methotrexate selectable retroviral vectors for Gaucher disease
Cannon et al. Retroviral vectors for gene therapy
Jolly et al. [2] High-efficiency gene transfer into cells
EP1511767B1 (de) Gereinigtes hüllprotein eines retrovirus, dafür kodierende nukleinsäuren, vektoren und deren verwendung
IL116216A (en) Eukaryotic cell lineages for recombinant viral retroviral RNA storage, using trans-expression vectors used to complete the trans
US7070992B2 (en) Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor
JPH11266885A (ja) ベクタ―成分の配列を含有するキメラポックスウイルス
JP2003530855A (ja) 遺伝子治療のためのベクター
Lang et al. Development of transforming function during transduction of proto-ras into Harvey sarcoma virus.
CA2199131C (en) Retroviral vector hybrids and the use thereof for gene transfer
Cannon et al. Retroviral vectors for gene therapy
WO2002064805A2 (en) Replication competent non-mammalian retroviral vectors
Logg Development of replication-competent retroviral vectors for efficient, targeted gene therapy of cancer

Legal Events

Date Code Title Description
FZDE Dead